Strides Pharma Science successfully concludes WHO inspection at Puducherry facility
Bengaluru: Strides Pharma Science Limited has announced that the company has successfully completed the inspection carried out by the World Health Organization (WHO) at its Puducherry facility.
The inspection was held between 16-20 January 2023.
The Puducherry facility caters to the U.S., Other Regulated Markets, and Institutional businesses and can produce finished dosage formulation products across multiple dosage formats.
Medical Dialogues team had earlier reported that the company had successfully concluded the EU GMP inspection carried out by the National Institute of Pharmacy and Nutrition (OGYÉI), Hungry at its Puducherry facility.
Read also: Strides Pharma successfully completes EU GMP inspection of Puducherry facility
Strides, a global pharmaceutical company headquartered in Bengaluru, India, is listed on the BSE and National Stock Exchange of India Limited (STAR). The Company mainly operates in the regulated markets and has an "in Africa for Africa" strategy and an institutional business to service donor-funded markets. The Company's global manufacturing sites are located in India (Chennai, Puducherry, and two locations in Bengaluru), Singapore, Italy (Milan), Kenya (Nairobi), and the United States (New York).
Next Story